Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label second-dose JVC-001 study in healthy Japanese children aged 5 to 6 years
jRCT2080225022Phase 3Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jan 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of measles, mumps and rubella vaccine (live) in measles, mumps and rubella, sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Antibody response against measles virus on Day 43, Antibody response against rubella virus on Day 43 and 1 more. Started Jan 2020; status: completed.
02
Drugs
measles, mumps and rubella vaccine (live)
03
Conditions
measlesmumpsrubella
Beyond the preview
Go deeper on jRCT2080225022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225022.